Olimel N12e

Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin, the active ingredient in Olimel N12e, is a mixture of essential and non‑essential amino acids presented as a sterile powder for intravenous use. It supports metabolic functions and protein synthesis in patients requiring nutritional supplementation.

GNH USA supplies Olimel N12e as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Olimel N12e provides a comprehensive amino‑acid profile tailored for clinical nutrition support. It is used in the following contexts: - Post‑operative recovery: Helps maintain nitrogen balance and supports tissue repair. - Severe malnutrition: Supplies essential amino acids to restore protein stores. - Critical illness or trauma: Contributes to metabolic stability and immune function. - Long‑term parenteral nutrition: Provides a balanced amino‑acid solution for patients unable to use the gastrointestinal tract.

Adverse reactions to Olimel N12e are generally related to its intravenous administration and the amino‑acid composition.

Common Side Effects: - Mild infusion‑site erythema - Transient nausea - Slight increase in serum urea - Temporary elevation of liver enzymes - Mild headache - Low‑grade fever

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reaction - Acute metabolic acidosis - Hyperammonemia - Severe electrolyte imbalance - Thromboembolic events - Renal dysfunction

When using Olimel N12e, clinicians should observe the following precautions: - Assess renal function: Adjust dosing in patients with impaired clearance. - Monitor liver enzymes: Watch for signs of hepatic stress. - Check electrolyte status: Correct imbalances before infusion. - Observe for hypersensitivity: Discontinue if severe reaction occurs. - Use aseptic technique: Prevent contamination during preparation. - Store at ambient temperature: keep in original container, protect from moisture and direct light.

Olimel N12e may interact with other agents administered intravenously. Awareness of the following interactions helps maintain safety:

Major Interactions (Avoid): - Concurrent high‑dose potassium chloride: risk of hyperkalemia. - Large-volume dextrose solutions: may cause osmotic shifts.

Moderate Interactions (Monitor Closely): - Loop diuretics: may exacerbate electrolyte loss. - Anticoagulants anticoagulants: alter clotting parameters. - Other parenteral nutrition modules: risk of cumulative amino‑acid excess. - Acid‑base modifying agents: affect metabolic balance. - Certain antibiotics antibiotics: may precipitate in mixed solutions.